Trial Profile
TREATMENT OF PRIMARY ACUTE MYELOID LEUKEMIA WITH THE COMBINATION OF IDARUBICIN, CYTARABINE AND GEMTUZUMAB OZOGAMYCIN (MYLOTARG) ASSOCIATED OR NOT TO G-CSF PRIMING: PROSPECTIVE STUDY OF EFFICACY AND TOXICITY.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 12 Nov 2021
Price :
$35
*
At a glance
- Drugs Gemtuzumab ozogamicin (Primary) ; Cytarabine; Granulocyte colony-stimulating factors; Idarubicin
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 08 Oct 2021 Results published in the Medicina Clinica
- 26 Jan 2021 Status changed from active, no longer recruiting to completed.
- 10 Aug 2016 Planned End Date changed from 1 Feb 2013 to 1 Dec 2016.